Gujarat Terce Laboratories has shared its financial results and business update for the quarter.

Revenue saw a 9% decline to ₹10.85 Cr, and EBITDA dropped by 51% to ₹0.07 Cr.

However, the net loss decreased by 44% to ₹0.04 Cr, and cash profit surged by 255% to ₹0.05 Cr.

The company is strategically evolving by divesting its manufacturing facility to become a lean, brand-focused organization, leading to a planned reduction in B2B sales.

Management emphasized strengthening fundamentals, including a 9% rise in Per Capita Per Month productivity, positioning for a stronger Q2 and sustained growth.